Cancer immunotherapy has been showing promising results and durable responses for lung cancer, breast cancer, head and neck cancer, and melanoma in various clinical trials studying the effects of blocking PD-1/PD-L1 interaction (118). This evidence concerns the gene CD274 and lung carcinoma.